Anavex Life Sciences Corp (AVXL)

[bb8675309]

Agree! Anavex reported positive top-line results from the second randomized, placebo-controlled AVATAR Phase 3 study (ANAVEX®2-73-RS-002) for the treatment of adult patients with Rett syndrome. The study met its primary and secondary efficacy and safety endpoints, with consistent and clinically meaningful improvements in all efficacy measures.

Financial Highlights:

Cash and cash equivalents of $151.1 million on December 31, 2021, compared to $152.1 million on September 30, 2021.